Education
About Us
Working with TipRanks
Follow Us
Entera Bio Ltd (ENTX)
NASDAQ:ENTX
ENTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.41 - $2.79
Previous CloseN/A
Volume29.71K
Average Volume (3M)39.45K
Market Cap
$109.01M
Enterprise Value$73.95M
Total Cash (Recent Filing)-$1.21M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.08
Next Earnings
May 09, 2025EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding45,420,677
10 Day Avg. Volume34,984
30 Day Avg. Volume39,445
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)725.48
Price to Cash Flow (P/CF)-8.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.22K
Enterprise Value/Ebitda-8.07
Forecast
1Y Price Target
$10.00Price Target Upside316.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Entera Bio News
PremiumCompany Announcements
Entera Bio Reports Transformative Year in 2024
PremiumCompany Announcements
Entera Bio Announces 2024 Financial Results and Updates
PremiumPre-Earnings
Entera Bio (ENTX) Q4 Earnings Cheat Sheet
PremiumCompany Announcements
Entera Bio Collaborates with OPKO for Oral GLP-1/Glucagon
---
Bulls Say, Bears Say
Bulls Say
CollaborationEntera Bio and OPKO Health have entered into a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide for obesity, metabolic, and fibrotic disorders.
FundingOPKO purchased roughly 3.7 million ordinary shares of Entera for $8 million, providing funding for Entera's share of the development costs.
Bears Say
Clinical Development RisksRisks include failure to advance EB613 or EB612 through clinical development in a timely manner and inability to secure a partner to optimize the commercial value of EB613.
Financial PerformanceEntera reported a net loss per share mainly driven by higher than expected operating expenses.
---
Ownership Overview
2.16% Insiders
0.04% Mutual Funds
1.34% Other Institutional Investors
96.47% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ENTX FAQ
What was Entera Bio Ltd’s price range in the past 12 months?
Entera Bio Ltd lowest stock price was $1.41 and its highest was $2.79 in the past 12 months.
What is Entera Bio Ltd’s market cap?
Entera Bio Ltd’s market cap is $109.01M.
When is Entera Bio Ltd’s upcoming earnings report date?
Entera Bio Ltd’s upcoming earnings report date is May 09, 2025 which is in 13 days.
How were Entera Bio Ltd’s earnings last quarter?
Entera Bio Ltd released its earnings results on Mar 28, 2025. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.08 by $0.02.
Is Entera Bio Ltd overvalued?
According to Wall Street analysts Entera Bio Ltd’s price is currently Undervalued.
Does Entera Bio Ltd pay dividends?
Entera Bio Ltd does not currently pay dividends.
What is Entera Bio Ltd’s EPS estimate?
Entera Bio Ltd’s EPS estimate is -0.07.
How many shares outstanding does Entera Bio Ltd have?
Entera Bio Ltd has 45,420,677 shares outstanding.
What happened to Entera Bio Ltd’s price movement after its last earnings report?
Entera Bio Ltd reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.08. Following the earnings report the stock price went down -2.857%.
Which hedge fund is a major shareholder of Entera Bio Ltd?
Currently, no hedge funds are holding shares in ENTX
---
Entera Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (316.67% Upside)
$10.00 (316.67% Upside)
Blogger Sentiment
Bullish
ENTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 296.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
20.00%
12-Months-Change
Fundamentals
Return on Equity
-103.34%
Trailing 12-Months
Asset Growth
-20.19%
Trailing 12-Months
Company Description
Entera Bio Ltd
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
---
ENTX Stock 12 Month Forecast
Average Price Target
$10.00
▲(316.67% Upside)
Technical Analysis
Black Diamond Therapeutics
―
Elicio Therapeutics
―
Aerovate Therapeutics
―
Tenaya Therapeutics
―
Ventyx Biosciences
―
Best Analysts Covering ENTX
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
+45.63%
reiterated a buy rating last month
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +45.63% per trade.
---